For the pathologist, the term 'mastopathy at risk' comprises a double aspect. On one hand, a good definition of the boundary between benign lesions and cancer. The latter uses mainly, and still now, morphological signs, and no 'markers' enable an infallible differentiation. Certainly certain criteria are useful observations to distinguish between intra-canal and intralobular epithelial hyperplasia of the carcinomas in situ, or to recognize between a tubular carcinoma and certain adenosis foci. But it is often the pathologist's experience which makes the difference. On the other hand, a good knowledge of the epidemiological studies associating, to each of the anatomopathological entities constituting the fibro-cystic mastopathy, a risk factor for breast cancer. Indeed, the pathologist must indicate, in his report, these various entities in order to help the clinician take his therapeutic decision. The results of the study of a population of 3305 women who have been examined at the Gustave Roussy Institute between 1970 and 1973 for benign mammary lesions, 401 on whom a biopsy was carried out, will illustrate this observation, revealing the importance of multiple fibro-adenosis foci, small cysts and lobe hyperplasias. But the histological details of these benign mastopathies must imperatively be integrated to the epidemiological and clinical data on the patient in order to adapt the therapeutic protocol for the best.
|Number of pages||4|
|Journal||Revue Francaise de Gynecologie et d'Obstetrique|
|Publication status||Published - 1991|
ASJC Scopus subject areas
- Obstetrics and Gynaecology